Roche subsidiary, Foundation Medicine, is boosting its presence in the MRD testing space, which it touts as “one of the fastest-growing areas within diagnostics”.

A virtual tool can facilitate cascade genetic testing for relatives of people with cancer who have pathogenic variants, ...

MethylScan is a low-cost blood test that detects cancers and organ diseases by analyzing DNA methylation, improving early diagnosis, and identifying disease origin.

A team of scientists from NTU Singapore has developed a new biochip that, when paired with artificial intelligence, can ...

ETHealthworld.com brings latest molecular diagnostics news, views and updates from all top sources for the Indian Health industry.

Ataraxis AI, a frontier artificial intelligence (AI) research lab developing AI-powered tools for oncology, today announced Ataraxis™ Breast NEO, a new predictive test within its Ataraxis Breast ...

Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that the company will present seven abstracts, including two oral sessions, at the American Association for ...

Overall, the incidence of colorectal cancer has decreased over the decades, largely in part due to the use of screening modalities, such as colonoscopy. Colorectal cancer is the second leading cause ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Liquid biopsies look for cancer signals in the blood, and while the tests for early ...

A new blood test could change the outlook for one of the deadliest cancers—pancreatic cancer—by catching it much earlier than ever before. Researchers identified two previously unknown proteins in the ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Lajos Pusztai, MD, ...

Broad endorsement for insurance-covered blood-based CRC screening (92%) suggests payer policy could materially influence uptake among guideline-eligible, average-risk adults starting at age 45.